Yubo International Biotech Limited
Symbool: YBGJ
PNK
0.325
USDMarktprijs vandaag
-175.4014
Koers/Winst Verhouding
-1.8389
Koers/Winst Groei Verhouding
38.94M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Yubo International Biotech Limited (YBGJ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0.4 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.4 | 0.3 | 0 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 0.8 | 1.1 | 1.9 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1.4 | 3.3 | 0.4 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0.1 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 1.6 | 3.5 | 0.5 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.5 | 0.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0.4 | 0.8 | 0.3 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1.1 | 1.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 2.9 | 4.7 | 1.3 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.1 | 0.1 | 0.1 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -3.7 | -2.5 | -0.9 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | 0.1 | 0 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2.9 | 2.1 | 2 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.6 | -0.1 | 1.2 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | 0.8 | 2.7 | -1.1 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 1.2 | 0.5 | 0.8 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.1 | -0.2 | 0 | ||||||||||||||||||||
cash-flows.row.inventory | 0 | -0.2 | -0.1 | -0.1 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 1 | 0.6 | 0.8 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.8 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.1 | 0.6 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0.1 | 1.4 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.1 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -1.4 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 1.4 | 0 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0.1 | -1 | 0.1 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -1.6 | 0 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0.1 | 1.2 | 1.4 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.1 | 0.4 | 0.1 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0.1 | 0.8 | 1.2 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 1.3 | 2.4 | 2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1.3 | 2.8 | 2.1 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | -1.2 | -1.5 | -0.7 |
Vaak gestelde vragen
Wat is Yubo International Biotech Limited (YBGJ) totale activa?
Yubo International Biotech Limited (YBGJ) totale activa is 2348551.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.390.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -2.586.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -2.620.
Wat is Yubo International Biotech Limited (YBGJ) nettowinst (netto-inkomen)?
De nettowinst is -1204765.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 790499.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 1257875.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.